{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:28Z","timestamp":1776408688083,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06913-5","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:19:17Z","timestamp":1774253957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["2g\/m2 Ara-c induced more favorable outcome than 1g\/m2 Ara-c in CLAG treatment for refractory or relapsed acute myeloid leukemia without increase toxicity: a multicenter propensity score matching analysis"],"prefix":"10.1007","volume":"105","author":[{"given":"Na","family":"liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-nan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng -wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-hang","family":"li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo-qing","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-hui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-ding","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"6913_CR1","first-page":"21","volume":"26","author":"WJ Edenfield","year":"1999","unstructured":"Edenfield WJ, Gore SD (1999) Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol 26(1):21\u201334","journal-title":"Semin Oncol"},{"issue":"2","key":"6913_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/10428190290006053","volume":"43","author":"T Robak","year":"2002","unstructured":"Robak T, Wrzesie\u0144-Ku\u015b A (2002) The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 43(2):281\u2013291","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"6913_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/jcm4040665","volume":"4","author":"NR Ramos","year":"2015","unstructured":"Ramos NR, Mo CC, Karp JE, Hourigan CS (2015) Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Med 4(4):665\u2013695","journal-title":"J Clin Med"},{"issue":"3","key":"6913_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"P Bose","year":"2017","unstructured":"Bose P, Vachhani P, Cortes JE (2017) Treatment of Relapsed\/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol 18(3):17","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"6913_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3324\/haematol.2009.013920","volume":"95","author":"C Craddock","year":"2010","unstructured":"Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N (2010) Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 95(6):989\u2013995","journal-title":"Haematologica"},{"issue":"14","key":"6913_CR6","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.2001.19.14.3340","volume":"19","author":"M Michallet","year":"2001","unstructured":"Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, Milpied N, Moreau P, Bordigoni P, Kuentz M, Sadoun A, Cahn JY, Soci\u00e9 G, Thomas X, Arnaud P, Raus N, Lh\u00e9ritier V, Pigneux A, Boiron JM (2001) Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19(14):3340\u20133349","journal-title":"J Clin Oncol"},{"key":"6913_CR7","doi-asserted-by":"crossref","unstructured":"Loke J, Buka R, Craddock C (2021) Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? Front Immunol 12:659595\u2013659595","DOI":"10.3389\/fimmu.2021.659595"},{"issue":"1\u20132","key":"6913_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10428190009053545","volume":"39","author":"T Robak","year":"2000","unstructured":"Robak T, Wrzesie\u0144-Ku\u015b A, Lech-Mara\u0144da E, Kowal M, Dmoszy\u0144ska A (2000) Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 39(1\u20132):121\u2013129","journal-title":"Leuk Lymphoma"},{"key":"6913_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12094-017-1798-8","volume":"20","author":"Y Bao","year":"2018","unstructured":"Bao Y, Zhao J (2018) Li3; Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study. Clin Transl Oncol 20:870\u2013880","journal-title":"Clin Transl Oncol"},{"key":"6913_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000493250","volume":"141","author":"Li Wanga Jun Xub Xiaolong Tianb Tingting Lv b Guolin Yuan","year":"2019","unstructured":"Li Wanga Jun Xub Xiaolong Tianb Tingting Lv b Guolin Yuan (2019) Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia. Acta Haematol 141:43\u201353","journal-title":"Acta Haematol"},{"key":"6913_CR11","doi-asserted-by":"publisher","unstructured":"Duan M, Zhang Y, Zhang M, Han X, Zhang Y, Yang C, Feng J, Zhang L, Zhang W, Li J, Tian L, Zhang Y, Zhou D. Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor\uff08CLAG\uff09regime in patients with refractory or relapsed acute myeloid leukemia. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.07.006","DOI":"10.3760\/cma.j.issn.0253-2727.2016.07.006"},{"key":"6913_CR12","unstructured":"Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Ho\u0142owiecki J, Kyrcz-Krzemien S, Grosicki S, Giebel S, Skotnicki AB, Pia\u02dbtkowska-Jakubas B, Kuliczkowski K, Kie\u0142bin\u00b4 ski M, Zawilska K, K\u0142oczko J, Wrzesien\u00b4 -Kus\u00b4 A. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group; European Journal of Haematology ISSN 0902-4441"},{"issue":"02","key":"6913_CR13","first-page":"0264","volume":"26","author":"G Li","year":"2018","unstructured":"Li G, Gangcan \u0f32enJL, Yunjie Z, Jia X, Fei G, Jinqian MJD, Feng L (2018) Song Yanping Xi\u0f07an Central Hospital, Xi\u0f07an Institute of Hematology, Shaanxi Xi\u0f07an 710003, China.The effectiveness comparison between the CLAG regimens and MEA regimens for the treatment of patients with relapsed or refractory acute myeloid leukemia. Mod Oncol 26(02):0264\u20130268","journal-title":"Mod Oncol"},{"key":"6913_CR14","doi-asserted-by":"crossref","unstructured":"Muluneh B, Buhlinger K, Deal AM, Zeidner JF, Foster MC, Jamieson KJ, Bates J, Van Deventer HW (2017) A Comparison of Clofarabine-based (GCLAC)and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed\/Refractory AML. Clin Lymphoma Myeloma Leuk 18(1):e13-8","DOI":"10.1016\/j.clml.2017.09.016"},{"key":"6913_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3324\/haematol.2010.030452","volume":"96","author":"G Borthakur","year":"2011","unstructured":"Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE (2011) Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96:62\u201368","journal-title":"Haematologica"},{"key":"6913_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood.V128.22.1069.1069","volume":"128","author":"A Perl","year":"2016","unstructured":"Perl A, Altman J, Cortes J, Smith C, Litzow M, Baer M, Claxton D, Erba H, Gill S, Goldberg S, Jurcic J, Larson R, Liu C, Ritchie E, Schiller G, Spira A, Strickland S, Ustun C, Wang E, Stuart R, Neubauer R\u20acolligC, Martinelli A, Bahceci G, E. &, Levis M (2016) Final results of the Chrysalis trial: a first-in-human phase 1\/2 dose-escalation, dose-expansion study of Gilteritinib (ASP2215) in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood 128:1069","journal-title":"Blood"},{"key":"6913_CR17","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","volume":"117","author":"M Levis","year":"2011","unstructured":"Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD (2011) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117:3294\u20133301","journal-title":"Blood"},{"key":"6913_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA et al (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130:722\u2013731","journal-title":"Blood"},{"key":"6913_CR19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S et al (2018) Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378:2386\u20132398","journal-title":"N Engl J Med"},{"key":"6913_CR20","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A et al (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103:e404\u2013e407","journal-title":"Haematologica"},{"key":"6913_CR21","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","volume":"98","author":"R Ram","year":"2019","unstructured":"Ram R, Amit O, Zuckerman T et al (2019) Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol 98:1927\u20131932","journal-title":"Ann Hematol"},{"key":"6913_CR22","first-page":"11899","volume":"44","author":"SA Rudnirk","year":"1979","unstructured":"Rudnirk SA, Cadman EC, Cap&i RL, Skeel RT, Bertino JR, McIntosh S (1979) Highdose cytosine arabinoside (HDARAC) m refractory acute leukemia. Cancer 44:11899\u201311193","journal-title":"Cancer"},{"key":"6913_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1182\/blood.V62.2.361.361","volume":"62","author":"RH Herzig","year":"1983","unstructured":"Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361\u2013369","journal-title":"Blood"},{"key":"6913_CR24","first-page":"200","volume":"6","author":"R Willemze","year":"1983","unstructured":"Willemze R, Fibbe WE, Zwaan FE (1983) Experience with intermediate and high dose cytosine arabinoside in refractory acute leukemia. Onkolosie 6:200\u2013204","journal-title":"Onkolosie"},{"key":"6913_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896\u2013903","journal-title":"N Engl J Med"},{"key":"6913_CR26","doi-asserted-by":"publisher","unstructured":"Park Y, Kang G, Kim D et al (2013) High-dose cytarabine consolidation (\u2265\u20091.5\u00a0g\/m2) might have shown a better outcomes than intermediate-dose cytarabine (1.0\u00a0g\/m2) combined with anthracyclines In AML patients who had achieved complete remissions in the first induction by standard 3\u2009+\u20097 regimen. Blood 124. https:\/\/doi.org\/10.1182\/blood.V122.21.2692.2692","DOI":"10.1182\/blood.V122.21.2692.2692"},{"key":"6913_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","volume":"32","author":"R Willemze","year":"2014","unstructured":"Willemze R, Suciu S, Meloni G et al (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32:219\u2013228","journal-title":"J Clin Oncol"},{"key":"6913_CR28","doi-asserted-by":"publisher","first-page":"e1566","DOI":"10.6061\/clinics\/2020\/e1566","volume":"75","author":"WFD Silva","year":"2020","unstructured":"Silva WFD, Rosa LID, Seguro FS et al (2020) Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clin (Sao Paulo) 75:e1566. https:\/\/doi.org\/10.6061\/clinics\/2020\/e1566","journal-title":"Clin (Sao Paulo)"},{"issue":"5","key":"6913_CR29","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","volume":"11","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, M\u00fcller LP, Schmid Cet et al (2024) Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol 11(5):e324\u2013e335","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06913-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06913-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06913-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:16Z","timestamp":1776405556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06913-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6913"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06913-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of 5th Medical Center of Chinese PLA General Hospital and the Ethics Approval Number was KY-2023-7-48-1, the study was conducted in accordance with the guidelines of the Declaration of Helsinki., Written informed consent was obtained from all patients in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}